Frazer Institute (FI)

The University of Queensland

Back to directory

People moving at the Diamantina Institute

The Frazer Institute at The University of Queensland brings together expertise in biomedical discovery, clinical research and applied health sciences to address major health challenges and improve outcomes for patients and communities.

Operating across Queensland's leading health innovation precincts at Herston and Dutton Park, the Institute supports research spanning discovery, clinical trials, implementation science and health system improvement. Research strengths include cancer, infection, immunology, brain and mental health, skin disease, ageing and chronic disease.

Clinicians, industry partners, government agencies and community organisations are encouraged to engage with the Institute. We provide a single point of access to multidisciplinary expertise and can connect partners with the research groups best aligned to their research, innovation or clinical priorities.

Website
https://frazer.uq.edu.au
Organisation type
  • University Research Institute
Number of research staff
500-700 research staff
Address
Frazer Institute, Translational Research Institute, 37 Kent Street, Woolloongabba, 4102

Strengths and capabilities

  • Discovery science and immunology
  • Preclinical and early‑phase research
  • Precision medicine and diagnostics
  • Clinical trial design and delivery
  • Multi‑centre and large‑scale trials
  • Health services and implementation research
  • Population health and chronic disease
  • Ageing, frailty and health systems
  • Evidence synthesis and policy translation
  • Clinical pharmacology and therapeutics
  • Biomarker discovery and molecular profiling
  • Data‑enabled and translational research
  • Hospital‑embedded research capability
  • National and global trial networks
  • End‑to‑end translational integration

Facilities and major equipment

  • Clinical Research Facilities (Herston and Dutton Park): dedicated clinical trial infrastructure supporting early‑phase to multi‑centre studies
  • Mass Spectrometry Services: advanced metabolomics and analytical platforms for biomarker and precision medicine research
  • Brisbane Breast Bank: a leading biobank supporting translational cancer research and clinical studies
  • TRI and ENTRI (Dutton Park): co‑located laboratories, imaging, clinical research and manufacturing capabilities enabling end‑to‑end translation
  • Pharmacokinetics analysis capability (Herston): Australia's only NATA accredited pharmacokinetic analysis capability to enable therapeutics development, including precision therapeutics

Lead researchers

  • Professor Gabrielle Belz FAA – Internationally recognised immunologist advancing immune cell biology and immunity to infection, inflammation and cancer.
  • Professor Ranjeny Thomas AM – Leading RESET RA, a novel immunotherapy aimed at achieving long-term remission in rheumatoid arthritis.
  • Professor H. Peter Soyer AC– Leads award-winning ACEMID research using AI and 3D imaging to improve melanoma detection.
  • Professor David Johnson – Chair, Australasian Kidney Trials Network, leading practice-changing international clinical trials in kidney disease.
  • Professor Ruth Hubbard – Director, Australian Frailty Network, advancing national frailty prevention, healthy ageing and health system reform.
  • Professor Brandon Wainwright AM - Leading development of personalised brain cancer vaccines and precision therapies for childhood cancers

Achievements of the centre

  • HPV vaccine (Gardasil)
    • Contributing to the elimination of cervical cancer in Australia
  • RESET Rheumatoid Arthritis immunotherapy
    • Early trials showed remission within 8 weeks.
  • AI‑enabled melanoma detection (ACEMID)
    • ​​​​​​​ National awards for advancing melanoma detection using AI and 3D imaging
  • MERINO clinical research network
    • Efficacy of treatment of hospital-acquired bloodstream infections
  • LACE and LACC trials
    • Informing the global surgical treatment approach for women diagnosed with endometrial and cervical cancer
  • World‑first lab‑grown human skin​​​​​​​
    • ​​​​​​​​​​​​​​Enabling disease modelling, drug development and regenerative medicine
  • Frailty and dementia risk discovery
    • ​​​​​​​International research enabling early intervention
  • The Australasian Kidney Trials Network (AKTN) leadership
    • ​​​​​​​Informing global practice and outcomes in kidney disease
  • The world's largest randomised clinical trial in infectious diseases (Bling-3)

Key science sectors

More information about the sectors this centre is involved in:

Update details

Is this your centre? See any issues? Send a request to update your listing.